Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.

The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A.

The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.